Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of Sutent in renal cancer brain metastases
2008-000948-13Phase 2Active
- Sponsor
- Institut Claudius Regaud
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in renal cell carcinoma (RCC) and brain metastases (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Intracranial objective response rate after 2 cycles. Started Apr 2008; status: active.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)brain metastases
Beyond the preview
Go deeper on 2008-000948-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000948-13.